Comparative Pharmacology
Head-to-head clinical analysis: ITRACONAZOLE versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ITRACONAZOLE versus VAGISTAT 1.
ITRACONAZOLE vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
200 mg orally once daily; for life-threatening infections, can be increased to 200 mg three times daily for first 3 days then twice daily. IV: 200 mg IV every 12 hours for 2 days, then 200 mg IV once daily.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
Clinical Note
moderateItraconazole + Tranilast
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast."
Clinical Note
moderateItraconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Tolfenamic acid."
Clinical Note
moderateItraconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide."
Clinical Note
moderateTerminal elimination half-life of itraconazole is approximately 24-36 hours after a single dose, but upon chronic dosing, the half-life increases to 34-42 hours due to saturable metabolism. For the active metabolite hydroxyitraconazole, half-life is similar. This prolonged half-life supports once- or twice-daily dosing.
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Itraconazole is extensively metabolized in the liver; the primary route of elimination is fecal (approximately 54% as metabolites, 18% as unchanged drug). Renal excretion accounts for about 35% of the dose, with <1% as unchanged drug. Bilary excretion also contributes.
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category D/X
Category C
Azole Antifungal
Azole Antifungal
Itraconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronic acid."